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Abstract: Stereotactic body radiation therapy (SBRT) is an effective 
and well-tolerated noninvasive treatment for medically inoperable 
patients with peripheral non–small cell lung carcinoma. The term 
“peripheral” refers to lesions that lie 2 cm or more from the mediasti-
num and proximal bronchial tree and was instituted based on results 
from a specific dose and fractionation schedule. Improvements in 
immobilization, respiratory motion management, and image guid-
ance have allowed for SBRT’s highly conformal and accurate deliv-
ery of large radiation doses per fraction. Results from prospective 
and retrospective studies suggest that lung SBRT has superior out-
comes when compared with conventionally fractionated treatments 
and is comparable with surgical resection. Investigations into the 
optimal SBRT dosing regimen for peripheral lesions are ongoing, 
with recent trials suggesting comparable efficacy between single 
and multiple fraction schedules. Chest wall toxicity after periph-
eral treatment is common, but it usually resolves with conservative 
management. Pneumonitis is less often observed after treatment 
of peripheral lesions, and changes in pulmonary function tests are 
minimal. Studies in the frail and elderly suggest that neither baseline 
pulmonary function tests nor age should preclude treatment. Recent 
technical developments have reduced delivery time and resulted in 
more conformal treatments. This review is on behalf of the IASLC 
Advanced Radiation Technology Committee.
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With the recent finding that computed tomography screen-ing of patients at high risk for developing lung cancer 
can reduce both cancer-related mortality and overall mortal-
ity, cancer screening of patients with reasonable life expec-
tancies and significant smoking histories is increasingly being 
encouraged. With such screening, non–small cell lung cancer 
(NSCLC), the most common lung cancer histology, will likely 
be identified more often and in earlier stages than in the past.1 
While surgery is still the preferred definitive treatment for 
patients with early stage lung cancer, many patients have sig-
nificant cardiac and pulmonary comorbidities often related 
to tobacco abuse that put them at high risk for complications 
and disability from surgical resection. For patients with such 
comorbidities or for patients who refuse invasive treatments, 
stereotactic body radiation therapy (SBRT) has emerged over 
the past decade as the standard of care for the medically inop-
erable patient with early stage lung cancer.
SBRT differs from conventionally fractionated radiation 
therapy in many ways. Instead of delivering radiation in small 
doses over a course of several weeks, SBRT delivers radia-
tion at very high doses and extremely precisely to carefully 
delineated targets over a brief period, typically no more than 1 
to 2 weeks. There are some variations in definitions such that 
the American Society for Radiation Oncology limits SBRT to 
a maximum of five fractions, but the European Organization 
for Research and Treatment of Cancer allows SBRT in up to 
eight fractions. Improvements in tumor staging, target delin-
eation, treatment planning, patient immobilization, respira-
tory motion management, and image guidance now allow 
for the reproducible delivery of these few, but large doses of 
radiation to a tumor with narrow margins. Delivery of these 
larger fractions allows for a higher biologically effective dose 
than with conventionally fractionated radiation therapy. At the 
same time, the narrower margins and sharper drop-off of dose 
(dose gradient) from the target help minimize injury to sur-
rounding normal tissue.
The location of this dose gradient ultimately determines 
the toxicity, but not the efficacy of SBRT. A prospective phase 
II study at Indiana University was the first to demonstrate 
that treatment of central and perihilar tumors had a higher 
risk of severe toxicity than treatment of peripheral tumors.2 
This central region was defined as within 2 cm of the proximal 
bronchial tree (Fig. 1). All patients in this study received 60 
to 66 Gy in three fractions. Those with central tumors had 
nearly a threefold increase in the rate of severe toxicity. With 
4 years of follow-up, the rate of severe toxicity was 10% in 
patients with peripheral tumors versus 27% in patients with 
central tumors.3 However, there was no difference in the 95% 
local control rate or median overall survival of 33 months by 
location. Several other studies have since showed similar dif-
ferences in toxicity, but not significant differences in overall 
survival between central and peripheral tumors (Table 1). 
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FIGURE 1.  Diagram showing the definition of the central tumor region, also known as the zone of the proximal bronchial tree. 
Copyright American Society of Clinical Oncology.
TABLE 1.  Studies Comparing Central Versus Peripheral NSCLC Lesions Treated with SBRT
Institution
Patients Overall Survival Local Control Severe Toxicity
P C F/u (Years) P (%) C (%) p P (%) C (%) p P (%) C (%) p
Asan Medical Center4 23 9 2 35 50 0.85 84 89 0.97 0 33 -
Erasmus MC-Daniel den Hoed5 32 6 2 50 17 0.07 100 100 - - - -
Indiana University3 48 22 3 - - 0.70 - - - 10 27 0.09
Julius- Maximilians University6 26 6 3 - - - - - - 16 9 -
Nagoya City University7 145 35 3 71 79 0.18 85 78 0.45 - - -
Technische Universität 
München8
68 24 3 41 29 0.65 89 64 0.04 - - -
University Hospital Brussels9 23 17 2 - - - 91 94 0.07 16 40 0.06
Washington University in St. 
Louis10
111 11 2 60 90 0.21 91 100 0.46 0 0 -
Yale University11 183 70 2 56 52 0.56 90 83 0.33 7 3 0.15
P, peripheral; C, central; F/u, follow-up; -, not reported; SBRT, stereotactic body radiation therapy; NSCLC, non–small cell lung carcinoma.
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However, these comparisons remain limited by the smaller 
number of central lesions that have been treated and reported. 
It should be emphasized that this concept of “peripheral” ver-
sus “central” lesions is closely linked to the dose and fraction-
ation employed. For example, longstanding series from Japan 
have not historically reported such location-dependent toxic-
ity rates when lower doses like 10–12 Gy per fraction have 
been utilized.
OUTCOMES
Fractionation
Due to the toxicity concerns raised by Indiana, the 
multi-institutional phase II RTOG 0236 limited enrollment 
to patients with peripherally located tumors. Without cor-
recting doses to the low density of the lung, this trial used 
homogeneous prescription doses of 60 Gy in three fractions. 
A subsequent analysis of phantom dosimetry obtained dur-
ing institutional credentialing for RTOG 0236 showed that 
the equivalent heterogeneous dose prescription was 54 Gy in 
three fractions.12 The study showed a 3-year primary tumor 
recurrence rate of 2%, a 3-year locoregional failure rate of 
13%, and a median survival of 4 years, more than double that 
expected with conventionally fractionated radiation therapy.13 
RTOG 0236 was recently updated showing a 5-year primary 
tumor recurrence rate of 7%, a 5-year locoregional recurrence 
rate of 38%, and a median overall survival of 4 years.14 These 
results have been replicated in numerous studies of peripheral 
lesions (Table 2).
Since there is no data yet published supporting the over-
all efficacy of one fractionation schedule over another, there 
are a variety of lung SBRT schedules described in the litera-
ture applicable to peripheral tumors. Perhaps the most extreme 
schedule involves single-fraction-based therapy. Early reports 
show SBRT doses being escalated from 15 Gy to 34 Gy with 
increasing success.22 At a single dose greater than or equal to 
30 Gy in one study, the local control rate was 83% with an 
overall survival of 41% at 2 years. The only grade 3 toxic-
ity in this high dose peripheral cohort was in a patient with 
active tuberculosis.23 Several other groups had no greater than 
or equal to grade 3 toxicities in their high dose single fraction 
cohorts.24,25 A recent retrospective single institution compari-
son of 30 Gy versus 34 Gy in a single fraction in 80 patients 
found no significant difference in toxicity, as well as no dif-
ference in 1-year overall and lung cancer-specific mortality.20
To more formally address the question of radiation dose 
and fractionation for peripheral tumors, RTOG 0915 is the first 
randomized phase II trial comparing 34 Gy in a single fraction 
versus 48 Gy in four fractions. With a median follow-up of 
just under 2 years, primary tumor control was 97% in both 
arms. Overall survival at 1 year was 85% in the single frac-
tion arm and 91% in the four fraction arm. Protocol-specified 
adverse events occurred in 10% of the single fraction patients 
and 13% of the four fraction patients.16 If these results are 
maintained with longer follow-up, a phase III trial compar-
ing a single fraction of 34 Gy compared with 54 Gy in three 
fractions (per RTOG 0236) has been proposed with a primary 
endpoint of overall survival.
With the results of such a trial, one would hope to build 
a consensus around the optimal number of fractions in lung 
SBRT for peripheral tumors. There continues to be consider-
able variation in treatment choice in the United States. For 
peripheral T1N0 tumors, only 1% of practicing radiation 
oncologists would use a single fraction. Most (56%) would 
use a three fraction regimen, with less choosing a four (18%) 
or five (25%) fraction regimen.26
Surgical Comparisons
Comparisons of local control of SBRT to surgery 
remain challenging and controversial, and these comparisons 
are not limited to the subsets of peripheral versus central lung 
tumors. A meta-analysis comparing 40 SBRT studies and 23 
surgery studies found that after adjusting for the proportion of 
operable patients and age, SBRT and surgery had similar esti-
mated overall and disease-free survival.27 Matched pair and 
propensity score comparisons of outcomes within individual 
academic institutions demonstrate similar overall survival, 
local-regional control, and distant control when controlled for 
TABLE 2.  Selected Series of Patients with Peripheral NSCLC Lesions Treated with SBRT
Location Patients Dose/Fxs Cohort Time (Years) OS (%) LC (%)
Grade 3+ Toxicity 
(%)
RTOG 0236, USA14 55 54/3 P 5 40 93 31
Sweden, Norway, & Denmark15 57 66/3 P 3 60 92 30
RTOG 0915, USA16 45 48/4 P 1 91 98 13
RTOG 0915, USA16 41 34/1 P 1 85 97 10
University of Miami, USA17 31 60–67.5/3–5 R 4.5 84 86 0
Hokkaido University, Japan18 41 40–48/4 R 3 47 57 5
University of virginia, USA19 40 42–60/3–5 R 2 45 83 2
Cleveland Clinic, USA20 25 34/1 R 1 64 86 0
Cleveland Clinic, USA20 55 30/1 R 1 75 98 0
University of Heidelberg, Germany21 32 26–30/1 R 1 - 100 0
Dose is reported in total Gy over number of fractions.
OS, overall survival; LC, local control; P, prospective cohort; R, retrospective cohort; RTOG, Radiation Therapy Oncology Group; SBRT, stereotactic body radiation therapy; 
NSCLC, non–small-cell lung carcinoma.
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patient selection factors.28,29 A single institution comparison 
of lobectomy and SBRT showed comparable patterns of fail-
ure for clinical stage I NSCLC.30 Only lobar control differed, 
but not primary tumor, regional, or distant control. This was 
despite 33% of surgery patients being upstaged by pathol-
ogy and 20% of surgery patients receiving adjuvant chemo-
therapy, whereas none of the SBRT patients received adjuvant 
chemotherapy.
Unfortunately, all randomized studies attempting a pro-
spective comparison between surgery and SBRT have failed. 
The randomized phase III studies Dutch ROSEL, RTOG 1021/
ACOSOG Z4099, and the STARS trial at M.D. Anderson have 
all been terminated secondary to slow patient accrual. However, 
a combined analysis of those who were enrolled and random-
ized on ROSEL and STARS showed a significant 3-year over-
all survival advantage in favor of SBRT, 95% versus 79% (p 
= 0.037). With a median follow-up of 3 years and a total of 
58 patients, recurrence-free survival was comparable at 86% 
and 80% (p = 0.54) between SBRT and surgery. The major-
ity of those treated with SBRT (87%) had peripheral lesions. 
Only 10% of patients treated with SBRT developed grade 3 
toxicity, whereas 44% treated with surgery developed grade 
3 and 4 toxicities. The only treatment-related death occurred 
in the surgery group. Although the patient numbers are small, 
this combined analysis suggests “at least equipoise between 
the two modalities” and that lobectomy with nodal dissection 
or sampling “results in an increased rate of procedure-related 
mortality and morbidity” when compared with SBRT.31
Apart from additional randomized studies between sur-
gery and SBRT, prospective cohorts of operable patients elect-
ing for SBRT will likely be the strongest evidence obtainable. 
RTOG 0618 is a completed phase II trial that looked at the 
use of SBRT in those patients with biopsy-proven peripheral 
NSCLC, who were deemed operable. It has shown a 2-year 
primary tumor failure rate of 7.7%, a 2-year involved lobe fail-
ure rate of 19.2%, and a 2-year overall survival rate of 84.4%.32 
JCOG 0403 is a similar Japanese phase II study which for oper-
able patients has shown a 3-year local progression-free survival 
rate of 68.5% and 3-year overall survival rate of 76%.33
TOXICITY
Chest Wall
Treatment of peripheral lesions may result in the chest 
wall receiving significant collateral dose. Damage to the 
chest wall may be expressed as skin, soft tissue, bone, and 
neurologic symptoms. Skin changes include acute erythema 
and ulceration as well as late hyperpigmentation and fibrosis. 
Acute skin changes typically occur 3 to 6 weeks after treat-
ment and severe toxicities are rare, seen in less than 10% of 
patients treated. The use of more than three beams and keeping 
the skin dose to less than half of the tumor prescription dose 
have been statistically linked to improved skin outcomes.34 
Limiting dose to the skin can be challenging, however, par-
ticularly in patients with tumors abutting the pleura and with a 
higher body mass index.35
Whereas almost all surgical patients will experience 
de facto chest wall pain due to the inherent invasiveness of 
the treatment, lung SBRT to peripheral lesions only produces 
neuropathic pain and symptomatic rib fractures in a minor-
ity of patients. Management replicates that used for surgical 
patients and is conservative. Anti-inflammatory medications 
are the primary analgesic followed by gabapentin or narcotics 
if required.36 Pain requiring intervention has been reported in 
up to 24% of patients and rib fracture in up to 42% of those 
with peripheral tumors treated by SBRT.37,38 However, around 
two-thirds of rib fractures will be asymptomatic.39 To date, no 
grade five chest wall toxicity has been reported. Female gender 
and obesity have been linked in multiple studies to increased 
chest wall toxicity. Patient predictive factors are not clearly 
defined, however. Studies conflict on whether younger40 or 
older41 patients are more susceptible. With respect to radiation 
delivery, the maximum dose delivered to the chest wall and 
the volume of chest wall receiving 30 Gy have been predictive 
of toxicity in multiple studies.42 Only recently has chest wall 
and rib delineation been required when planning treatments 
on multi-institutional trials, although a consensus dose con-
straint has yet to defined.
Pneumonitis
A historic concern with delivering higher effective 
doses to the lung with lung SBRT has been the potential for 
increasing pulmonary toxicity in patients with already limited 
respiratory reserve. Of note, grade three to four pulmonary 
complications occurred in 16% of the patients with peripheral 
tumors in RTOG 0236.13 However as noted by the authors, 
these findings were not primarily patient symptom related but 
rather related to prespecified changes in pulmonary function 
tests (PFTs). In contrast to conventionally fractionated radia-
tion where the mean lung dose and the volume of lung receiv-
ing 20 Gy predict for pneumonitis, toxicity with peripheral 
SBRT does not correlate with any such dosimetric parameters. 
Sharp dose gradients and the fact that peripheral tumors are 
far from large airways likely are responsible for this minimal 
toxicity when compared with studies of central lesions. It 
remains difficult, nonetheless, to separate treatment toxicity 
from exacerbations of underlying pulmonary disease common 
in lung cancer patients.
Several retrospective studies have concluded that PFTs 
change minimally43 after SBRT for peripheral lesions and that 
poor baseline PFTs do not correlate with decreased survival.44,45 
More interestingly given that it was a prospective, multi-insti-
tutional study, in RTOG 0236, the mean percent decline in 
forced expiratory volume in 1 second and the mean percent 
decline in diffusing capacity for carbon monoxide were both 
6% 2 years following treatment.46 There were minimal changes 
in arterial blood gases after treatment, and there were no sig-
nificant changes in oxygen saturation. Baseline PFT values did 
not predict for pneumonitis or decreased overall survival when 
adjusted for cardiac comorbidity. Thus, lung SBRT remains 
a safe modality in a very fragile population, and poor PFTs 
should not be used to exclude patients from treatment.
Elderly
Inasmuch as poor baseline pulmonary status should not 
exclude patients with peripheral NSCLC from lung SBRT, 
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neither should patient age. A study of patients over the age 
of 75 years showed a 3-year local control of 89%, a 3-year 
overall survival of 45%, and grade three toxicity limited to 
less than or equal to 10% of patients.47 The majority (84%) 
in this study had peripheral tumors. A study of octogenarians 
in which all but one patient had peripheral disease reported 
no severe toxicity after SBRT and a 2-year overall survival of 
74% with no local failure.48 National population-based stud-
ies of the elderly with early stage NSCLC have shown that 
an increase in the utilization of SBRT over time leads to an 
increase in overall survival. This survival increase is limited 
to those treated with radiation and is not observed in those 
who received surgery or no treatment over the studied time 
periods.49 Overall, tolerance of SBRT has proven comparable 
with younger patients.50
DELIVERY
SBRT is often delivered using 7–12 noncoplanar static 
beams with each day of treatment lasting between 20 and 45 
minutes including patient set-up, verification, and treatment 
delivery. However, prolonged treatment sessions are associ-
ated with intrafractional shifts in the position of both tumor 
and patients. If treatments take longer than half an hour, mean 
intrafraction tumor deviation may exceed 5 mm.51 Attempts 
to decrease treatment time and therefore these shifts include 
removing flattening filters52 from the beam to increase the 
dose rate, as well as treatment with arcs,53 in which the treat-
ment machine rotates about the patient continually deliver-
ing dose. Such treatment plans can cut the delivery time to as 
much as a third.54 Delivery with arcs can result in a more con-
formal treatment and in a decrease in chest wall dose with the 
trade-off of increased low dose to the contralateral lung.55,56 
However, treatment with arcs has also been associated with 
more radiographic pulmonary changes in comparison to treat-
ment with fixed field beam arrangements.57
The optimal time interval over which peripheral NSCLC 
should be treated is unknown. Just as there have been a range 
of lung SBRT dose schedules, there are varieties of deliv-
ery timetables. Fractions have been delivered in consecutive 
days or with breaks of varying duration. The uninterrupted 
approach to delivery may minimize malignant cell repopula-
tion and for patients may be more convenient. The “gapped” 
approach theoretically may allow for more sub-lethal damage 
repair of normal tissues and a decrease in toxicity. The only 
randomized study to address this question compared patients 
with peripheral tumors treated in four fractions over either 4 
or 11 days.58 Overall quality of life scores were not different at 
1 and 4 months between the groups, although patients in the 
4-day group experienced a clinically meaningful worsening in 
dyspnea (expressed as a rate of grade two or higher events). 
There was an imbalance between treatment groups, however, 
with the 11-day cohort having worse respiratory symptoms at 
baseline. Late toxicity and disease control were not addressed 
by this study, leaving the optimal treatment duration undefined.
SBRT with particle therapy is also being explored in an 
attempt to minimize toxicity. Treatment with protons or car-
bon ions may alter toxicity profiles since they lack an exit dose 
when compared with photons. Particle treatment planning in 
the lung is complicated, however, as the air and soft tissue 
interfaces that move with respiration create distal range uncer-
tainties. Also, treatment is often done with two to three beams 
which can generate larger volumes of high dose than photons, 
particularly in the chest wall with peripheral lesions.59 Despite 
this, comparisons of particle versus photon plans for patients 
with tumors within 2.5 cm of the chest wall show that particles 
can still reduce the chest wall doses at all levels measured.60 
Particles also allow for sparing more of the lung, heart, and 
esophagus, but the clinical relevance of these findings is 
uncertain and specifically for patients with peripheral tumors, 
these at-risk organs are often far from the target, with already 
limited exposures to dose with photon-based SBRT.61
CONCLUSION
Regardless of delivery method and treatment schedule, 
SBRT is an effective and well-tolerated noninvasive treatment 
for medically inoperable patients with peripheral NSCLC. 
Prospective and retrospective studies of lung SBRT suggest 
that it has superior outcomes with minimal toxicity when 
compared with conventionally fractionated treatments. This 
toxicity appears dose schedule and location dependent, result-
ing in the concepts of peripheral and central lesions. These 
terms currently inform outcome analysis in lung SBRT as well 
as trial stratification. Investigations into the effectiveness of 
SBRT in operable patients as well as the optimal dosing regi-
men are ongoing.
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